A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC-4401C in Healthy Subjects
Latest Information Update: 18 Sep 2021
At a glance
- Drugs GC 2107 (Primary)
- Indications Coronary thrombosis
- Focus Adverse reactions
- 04 Sep 2012 New trial record
- 29 Aug 2012 Biomarkers information updated